ERS 2023: FeNO measurement for doctors and patients

Currently, an observational study with 80+ asthma patients is ongoing to investigate the impact of FeNO home measurement on asthma therapy. The FeNO@home study commissioned by Bosch is being conducted by 4 study centers in Germany and Italy. Although not yet completed, initial case reports suggest that FeNO home monitoring can benefit both physicians and patients: Collecting asthma-related patient data over time can help in early detection of exacerbation risk, predicting ICS and biologic efficacy, improving treatment adherence, as well as monitoring and optimizing medication. The investigators will present their first case reports at ERS.

Case Report 1, Case Report 2, Case Report 3,
Case Report 4, Case Report 5

Bosch Healthcare provided its Vivatmo me home measurement device and the Vivatmo app asthma diary for the FeNO@home study. Although final results are pending, it is becoming apparent that FeNO home monitoring can

• improve the quantity and information value of patient data
• and significantly reduce study coordination efforts.

Although patients need to visit the study centers less frequently, they contribute more FeNO values over time and provide additional contextual information via the companion app. The cost-effective enhancement of the patient dataset can be valuable in research as well as help specialists to improve asthma management.

Our products are designed to ensure that not only patients have an optimal user experience. We also want the technical effort for administration and integration to be as low as possible. This gives healthcare professionals working in clinics, medical practices, or on studies more time to focus on the essentials. The Vivatmo system provides smart connectivity solutions that allow FeNO measurements to be integrated into daily routines as easily and efficiently as possible:

• Remote software updates and device management via Vivasuite – the secure and smart cloud solution for medical devices from Bosch.
• Easy integration with Healthcare Information Systems (HIS) via standard interfaces such as HL7 and GDT.
• Patients who measure their FeNO values at home can easily transfer them to the Vivatmo app via Bluetooth. In the app, they can also document symptoms, medication intake as well as pollen counts, and share data reports (CSV or PDF) with their treating physician.
• Medical study initiators and CROs who focus on home measurement to improve dataset and cost efficiency can easily integrate FeNO values and other relevant patient data into their IT systems using our Software Development Kit (SDK).
• Portable, wireless handheld allows mobile measurements. Data is subsequently transmitted to the Vivatmo app or the basestation via Bluetooth.

Vivalytic combines a wide range of molecular diagnostic tests for the point-of-care in just one system – fully automated, intuitive, and reliable. The comprehensive test portfolio also includes PCR tests for the detection of respiratory pathogens such as as SARS-CoV-2, Influenza, and RSV. Further tests are currently under development, for example Vivalytic VRI and Bordetella.